CDH17 Phase 1/2 trial, page-12

And here it is:

Investor Update Webinar

Sydney, Australia, 28 February 2025:Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce that CEO Dr Rebecca McQualter will conduct an investor webinar following yesterday’s news on $4m of non-dilutionary funding and an update on the CHM CDH17 CAR-T trial. When:11am AEDT, Monday 3 March Register at: https://us02web.zoom.us/webinar/register/WN_l7irJOaSSqKtFgXcnplKNg Upon registering attendees will receive an email containing information about joining the webinar. A recording will be available at the above link soon after the conclusion of the live session, with the replay to also be made available via Chimeric’s website and social media channels. Questions can be sent in advance of the webinar to[email protected].